Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENT-iT: Infection Prophylaxis in Total Joint Replacement
NCT06126614Phase 3Recruiting
- Sponsor
- Hamilton Health Sciences
- Start
- May 2024
- Primary completion
- Nov 2028
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Hydrogel Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of vancomycin, chlorhexidine and IVIEW-1502 in periprosthetic joint infection (PJI) (6 arms), sponsored by Hamilton Health Sciences. Primary endpoint: Number of reoperations due to infection at 1 year. Started May 2024; status: recruiting.
02
Drugs
vancomycinchlorhexidineIVIEW-1502
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on NCT06126614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126614.